Neuphoria Therapeutics Inc.
corporate_fare Company Profile
Neuphoria Therapeutics Inc. (NASDAQ:NEUP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for NEUP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-18, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for NEUP spans 10-K, DEFA14A, 8-K, 10-Q.
Recent high-impact activity:
- Neuphoria 10-K Reveals Material Weakness, $5.4M Goodwill Impairment, and Restructuring Details
- Neuphoria Enters All-Share Merger with Scancell, Backed by $53.6M+ Financing
- Neuphoria Enters All-Share Merger with Scancell; Combined Company to Focus on Immuno-Oncology
- Neuphoria Agrees to All-Share Merger with Scancell, $89M Financing Secured
- Neuphoria Therapeutics Confirms Acquisition Discussions with Scancell
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 12,377 shares in NEUP as of the October 30, 2026 settlement, a 92.5% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 53.7% of NEUP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.